SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (25840)9/29/1998 3:06:00 PM
From: RXGOLF  Read Replies (1) | Respond to of 32384
 
Does anyone have more info on their "morphine pill". I am not familiar with their product. Is it immediate release, long acting, etc, etc.? Currently, Purdue Frederick is a major player in the U.S. morphine market with their MS Contin. It isn't cheap, with 100 tablets of the 60mg morphine long acting costing the patient over $300.00 dollars(ie).



To: bob zagorin who wrote (25840)9/29/1998 3:21:00 PM
From: Henry Niman  Respond to of 32384
 
I had guessed that LGND was looking to get into neurosciences with the SERM connection and John Groom on their board. When ELN bought ATHN, I thought that a deal with LGND could be in the cards. I have to look a bit harder at NBIX, but Robinson is on their board, and there could be some synergies there.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News